Vtv Therapeutics Stock Price, News & Analysis

vTv Therapeutics (Nasdaq: VTVT) announced the start of a mechanistic phase 1 study to evaluate TTP399, a liver-selective glucokinase activator, in people with type 1 diabetes. This study focuses on the effects of TTP399 on ketone formation during insulin withdrawal, aiming to demonstrate that it does not increase ketone production, a precursor to ketoacidosis. Previous phase 2 studies showed TTP399 improved glycemic control without raising the risk of ketoacidosis or hypoglycemia. The company plans to initiate a pivotal study later this year.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled virtually for March 9-10, 2021. During the event, the company will offer a general update through an on-demand presentation starting March 9, and management will hold one-on-one virtual meetings with investors. vTv focuses on developing oral treatments for type 1 diabetes and inflammatory diseases, with a clinical pipeline that includes indications for other diseases such as type 2 diabetes and COPD.

vTv Therapeutics Inc. (Nasdaq: VTVT) reported its financial results for Q4 2020, showing a revenue of $6.4 million, driven primarily by a licensing agreement with Anteris Bio. The company transitioned from a net loss of $2.3 million in Q3 2020 to a net income of $1.6 million in Q4. The Phase 2 SimpliciT-1 study results for TTP399 were published, showing significant reductions in HbA1c for type 1 diabetes patients. The firm plans to initiate pivotal trials for TTP399 in H2 2021 and has a cash position of $5.7 million.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced promising results from the JDRF-supported SimpliciT-1 Study published in Diabetes Care. The study evaluated the safety and efficacy of TTP399, a glucokinase activator, in adults with type 1 diabetes (T1D). Findings showed a statistically significant reduction in HbA1c and a clinically meaningful 40% decrease in severe hypoglycemic events compared to placebo. The results suggest TTP399's potential as a viable adjunctive therapy for T1D, with further studies planned for later this year.

vTv Therapeutics (Nasdaq: VTVT) announced the initiation of a Phase 1 multiple ascending dose study for the orally administered PDE4 inhibitor, HPP737. This study aims to assess safety and pharmacokinetics in healthy volunteers and will help determine the optimal dose for a planned Phase 2 study in psoriasis. The trial is expected to conclude by Q2 2021. Additionally, strategic partner Newsoara Biopharma has started a Phase 2 study in COPD in China, following favorable Phase 1 results. HPP737 shows promise as a well-tolerated treatment with strong efficacy in preliminary assays.

vTv Therapeutics, a clinical-stage biopharmaceutical company, announced participation in the LifeSci Partners 10th Annual Healthcare Corporate Access Event from January 11-14, 2021. The event will be held virtually, allowing company management to conduct one-on-one meetings concurrently with J.P. Morgan’s 39th Annual Healthcare Conference. vTv focuses on developing oral treatments for type 1 diabetes and inflammatory diseases, alongside pursuing additional indications in areas like type 2 diabetes and chronic obstructive pulmonary disease.

vTv Therapeutics (Nasdaq: VTVT) has announced that its Phase 2 Elevage study of azeliragon for mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of improving cognitive function as measured by ADAS-cog14. The trial involving 43 participants showed a 1.8-point decline in the azeliragon group compared to 0.35 in the placebo group, with the differences not being statistically significant. Despite this, azeliragon was well-tolerated. The company will continue analyzing the data for future applications.

Aditum Bio announces the formation of Anteris Bio, its third portfolio company, aimed at developing new therapies for renal disease following the successful in-licensing of ANT-401 from vTv Therapeutics (NASDAQ:VTVT). Chronic kidney disease, affecting nearly 700 million globally, has limited effective treatments. ANT-401 activates Nrf2, presenting potential for modifying renal disease progression. Aditum partners with TrialSpark to enhance clinical trial efficiency, offering faster recruitment through innovative methods.

vTv Therapeutics has signed a licensing agreement with Anteris Bio for its Nrf2 activator compound, HPP971, aimed at renal disease treatment. Anteris will pay vTv $2 million upfront and may provide up to $151 million in future milestones, along with royalties on sales. HPP971, which has completed two Phase 1 studies, will be renamed ANT-401 and may address chronic kidney disease (CKD), affecting 700 million globally. vTv continues to seek development opportunities for its other Nrf2 compounds.